Clinical Trial

BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

Study acronym: AREAL
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).
Trial Details
NCT Number NCT07108309
Lead Sponsor Biocad
Conditions Triple Negative Breast Cancer
Enrollment 124 participants
Start Date 2024-07-15
Primary Completion 2025-12 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-08-07